Last reviewed · How we verify
Duovent HFA
Duovent HFA is a combination inhaler containing ipratropium bromide (anticholinergic) and albuterol/salbutamol (beta-2 agonist) that works synergistically to relax airway smooth muscle and improve bronchodilation.
Duovent HFA is a combination inhaler containing ipratropium bromide (anticholinergic) and albuterol/salbutamol (beta-2 agonist) that works synergistically to relax airway smooth muscle and improve bronchodilation. Used for Chronic obstructive pulmonary disease (COPD) maintenance therapy, Acute bronchospasm relief in COPD patients.
At a glance
| Generic name | Duovent HFA |
|---|---|
| Sponsor | Centre Hospitalier Universitaire UCLouvain Namur |
| Drug class | Combination bronchodilator (anticholinergic + beta-2 agonist) |
| Target | Muscarinic acetylcholine receptors (M3) and beta-2 adrenergic receptors |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | FDA-approved |
Mechanism of action
Ipratropium blocks muscarinic acetylcholine receptors to prevent bronchoconstriction, while albuterol stimulates beta-2 adrenergic receptors to promote bronchial smooth muscle relaxation. The combination provides complementary bronchodilation through two distinct mechanisms, offering improved airflow compared to either agent alone.
Approved indications
- Chronic obstructive pulmonary disease (COPD) maintenance therapy
- Acute bronchospasm relief in COPD patients
Common side effects
- Tremor
- Headache
- Palpitations
- Dry mouth
- Nervousness
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |